GSK

Brentford, United Kingdom Founded: 1715 • Age: 311 yrs Listed Acquired By Unilever
Developer of pharmaceuticals and vaccines for various therapeutic areas

About GSK

GSK is a publicly listed company based in Brentford (United Kingdom) founded in 1715, and was acquired by Unilever in December 2018. Developer of pharmaceuticals and vaccines for various therapeutic areas. The company has 91,864 employees. GSK has completed 23 acquisitions, including 35Pharma, Affinivax and Aiolos Bio. Its chief executive, as recorded, is Dame Emma Walmsley. Its website gsk.com draws about 1.3 million monthly visits. Its Indian entity Glaxosmithkline Pharmaceuticals Limited reported revenue of β‚Ή3,988 Cr. Its focus areas include Diversified Pharmaceuticals.

Company details

Founded in 1715, GSK operates in the pharmaceutical sector, with a focus on research, development, clinical trials, and commercialization of medicines and vaccines. Treatments are provided for respiratory, immunology, inflammatory, oncology, HIV, and infectious diseases. Global access to products is emphasized, alongside sustainable practices, from its base in Brentford, United Kingdom.

  • Headquarters Brentford, United Kingdom
  • Employees 91,864
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website gsk.com/en-gb
  • Social LinkedIn X Facebook Instagram YouTube
  • Acquired by Unilever (Dec 2018)
  • Legal Name Gsk Plc
Key Metrics
  • Market Cap
    ₹44,693 Cr

    GLAXO · NSE

  • Share Price
    ₹2,713.40

    +2.85% today

  • Revenue
    ₹3,822 Cr

    FY 2025-26 · +1.9% YoY

  • EBITDA
    ₹1,309 Cr

    Margin 34.3%

  • Net Profit
    ₹962 Cr

    FY 2025-26 · +10.1% YoY

  • P/E (TTM)
    39.6x

    P/B 23.9x

  • ROE
    49.1%

    ROCE 59.0%

  • Debt / Equity
    0.01

    Interest cover 0.2x

  • Latest Funding Round
    $415.25K (USD), Grant

    Dec 2023

  • Investors
    Unilever

    & 9 more

  • Employee Count
    91,864
  • Investments & Acquisitions
    35Pharma

    & 22 more

  • Acquired by
    Unilever

    (Dec 2018)

Apps and channels of GSK

its YouTube channel ViiV Healthcare has 133 subscribers and 30 videos.

ViiV Healthcare
YouTube 133 subscribers 30 videos Autos & Vehicles
Open channel

Videos from GSK

The most watched videos on GSK's YouTube channel, ViiV Healthcare (133 subscribers). Click a video to play it here.

Bridging the gap between clinical trials and real life in HIV care
532.5K views
The potential of bNAbs
11.4K views
Take My Hand
2.2K views
We can end the HIV epidemic, FULL STOP.
1.9K views

More on ViiV Healthcare.

Funding Insights of GSK

  • Total Rounds 29
  • Last Round Grant β€” $415,246
  • First Round $393,750

    (Jul 2008)

  • Investors Count 9

Latest 10 of 29 funding rounds of GSK with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2023$415,246Grant––
Nov 2023$433,387Grant––
Nov 2023$909,024Grant––
Apr 2023$106,185Grant––
Apr 2023$126,591Grant––
Jun 2022$247,384Grant––
Sep 2021Post-IPO––
Apr 2021Post-IPO––
Mar 2021$8.2MGrant––
Aug 2020Grant––
Valuation history

10 investors in total: 10 institutional.

Investors in GSK

GSK has secured backing from 10 investors, including institutional investors. Prominent investors backing the company include Unilever, Elliott Management and Scottish Enterprise.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
economie.gouv.fr
mhsr.sk
Activist investing in undervalued European public equities through engagement.
2019bluebellcp.comLondon, United Kingdom
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed.
2016carb-x.orgBoston, United States
Government entity focused on information and services
2000usa.govUnited States
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
Business development and leadership training programs are offered to companies.
1991scottish-enterprise.comGlasgow, United Kingdom
Multiple sectors are invested in by the hedge fund.
1977elliottmgmt.comNew York, United States
Administers health care and support for military personnel and operations.
health.milFalls Church, United States
A global consumer goods business with diverse product offerings.
1872unilever.comLondon, United Kingdom
Premium access

Investor details for GSK

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Glaxosmithkline Pharmaceuticals Limited (GSK)

Glaxosmithkline Pharmaceuticals Limited is the primary company behind GSK. The board of Glaxosmithkline Pharmaceuticals Limited currently have 8 directors; the longest-serving is Subesh Ronald Williams, appointed in 2017. 32 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Subesh Ronald Williams
DIN 07786724
Director07 Apr 20179 yrs 7 moGlaxosmithkline Pharmaceuticals Limited
Renu Sud Karnad
DIN 00008064
Director01 Apr 20197 yrs 7 moGlaxosmithkline Pharmaceuticals Limited
Sunita Maheshwari
DIN 01641411
Director18 May 20206 yrs 6 moGlaxosmithkline Pharmaceuticals Limited
Manu Anand
DIN 00396716
Director16 May 20224 yrs 6 moGlaxosmithkline Pharmaceuticals Limited
Bhushan Arun Akshikar
DIN 09112346
Managing Director01 Dec 20223 yrs 11 moGlaxosmithkline Pharmaceuticals Limited
Somasundaram Palamadairamaswamy
DIN 00356363
Director26 Mar 20251 yr 7 moGlaxosmithkline Pharmaceuticals Limited
Anup Wadhawan
DIN 03565167
Director26 Mar 20251 yr 7 moGlaxosmithkline Pharmaceuticals Limited
Ronojit Biswas
DIN 07684843
Whole-Time Director01 Apr 20267 moGlaxosmithkline Pharmaceuticals Limited

People of GSK

963 people are tracked at GSK (579 in leadership, 9 in board & advisors, 375 in team); the tracked headcount is 91,864.

NameRoleGroup
Dame Emma Walmsley
CEOLeadership
Julie Brown
CFOLeadership
Enoch Acquah
Production Value Stream DirectorLeadership
Rosirene Paczkowski
DirectorLeadership
Avijit Ray
DirectorLeadership
John Hong
Medicine Supply Chain Leader (director)Leadership
Angela Avila
Finance DirectorLeadership
Sarit Cohen-Rabbie
Clinical Development Director, ImmunologyLeadership
Renata Scofield
Global Senior Director, Environmental StewardshipLeadership
David Redfern
President, Corporate DevelopmentLeadership
Jiaying Ji
Head Of China Talent AcquisitionLeadership
Sean Evans
Director, Strategic AlliancesLeadership
Sergio Serrano Caballero
Digital Business PartnerLeadership
Heidi Feldser
Scientific DirectorLeadership
Kyle Robinson
Associate Director External OperationsLeadership
Christophe Lambert
Head Of Viral Computational GenomicsLeadership
Rajesh Gurumurthy
Director Strategic Procurement (senior Principal Product Owner) Global Products & TechnologyLeadership
Victoria Sanchez Zini
Director R&d Strategy - RD Strategy & Portfolio Management / Office Of The CSOLeadership
Cristelle Noirhomme
Head Of Belgium Corporate Government AffairsLeadership
Yogitaa Gahlot Saha
Director - FinanceLeadership

943 more people are available in the full profile.

Premium access

Complete people profiles for GSK

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of GSK

GSK is a publicly listed company on the LSE with ticker symbol GSK in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Jun 2003
  • Listed onNSE: GSKCONS
  • Listed entityGSK plc
  • Exchange sectorHealth technology
  • ISINGB00BN7SWP63
  • Share price1,759.00 GBX (+0.34% on the day) · 2026-10-14
  • Market capitalisation70,243,247,725.00 GBX
  • Price to earnings14.9
  • EPS (diluted, trailing year)1.18 GBX
  • Dividend yield3.88%
  • Volume (last session)624,599

Financials of GSK

Exchange-reported figures of Glaxosmithkline Pharmaceuticals Limited, the listed company behind GSK (NSE: GLAXO).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹3,822 Cr
+1.9% YoY
EBITDA
₹1,309 Cr
+11.2% YoY
Profit After Tax
₹962 Cr
+10.1% YoY
Net Worth
₹2,267 Cr
+16.2% YoY
Total Assets
₹2,561 Cr
+15.9% YoY
Total Debt
₹33.27 Cr
+234.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,8223,7493,4543,2523,2782,9263,224
Revenue growth+1.9%+8.6%+6.2%-0.8%+12.1%-9.3%-
EBITDA1,3091,177745793740389(231)
EBITDA margin+34.3%+31.4%+21.6%+24.4%+22.6%+13.3%-7.2%
Profit before tax1,4061,2608168392,093525306
Net profit9628746575901,684476144
Net profit margin+25.2%+23.3%+19.0%+18.1%+51.4%+16.3%+4.5%
EPS (β‚Ή)61.1554.7634.8336.05100.0421.145.50
Balance sheet
Total assets2,5612,2102,0442,0122,9471,7742,111
Net worth2,2671,9511,7781,7412,6631,4781,821
Total debt33.279.9518.6715.5420.0834.630.18
Cash & bank1,3911,4041,0631,1562,4851,1581,083
Net working capital4523944726621,656862751
Cash flow
Cash from operations9031,290582484811578490
Cash from investing397(45.80)8.71808(406)418(56.84)
Cash from financing(737)(769)(562)(1,543)(524)(696)(428)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,1849389951,041980805974949
Revenue growth (YoY)+20.8%+16.6%+2.2%+9.7%-3.1%-1.2%--
Other income72.7843.7635.9550.1036.2143.7240.6835.07
EBITDA402296351371336251333292
EBITDA margin+34.0%+31.5%+35.3%+35.7%+34.3%+31.2%+34.2%+30.7%
Depreciation15.0215.8413.1720.3217.4315.5214.7218.80
Interest0.490.970.611.190.510.420.580.09
Profit before tax459322373400354279359308
Tax12385.2795.2410496.5173.9795.7078.22
Net profit336237278296257205263230
EPS (β‚Ή)19.8314.0016.4017.4515.0212.1015.5213.57
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,7903,7233,4073,2163,2182,9203,225
Revenue growth+1.8%+9.3%+5.9%-0.0%+10.2%-9.4%-
EBITDA1,3001,169737788734389(213)
EBITDA margin+34.3%+31.4%+21.6%+24.5%+22.8%+13.3%-6.6%
Profit before tax1,3761,2488098352,087524322
Net profit9088276515871,679475197
Net profit margin+24.0%+22.2%+19.1%+18.2%+52.2%+16.3%+6.1%
EPS (β‚Ή)59.7354.2534.5135.8899.7921.116.50
Balance sheet
Total assets2,5342,2082,0492,0232,9611,7922,130
Net worth2,2411,9491,7841,7532,6781,4971,840
Total debt33.279.9518.6715.5420.0834.630.18
Cash & bank1,3551,4011,0611,1512,4791,1581,066
Net working capital4113724546441,643866755
Cash flow
Cash from operations8811,280579488820595491
Cash from investing385(36.53)14.97805(420)408(63.10)
Cash from financing(737)(769)(562)(1,544)(524)(696)(428)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,1809249891,023974805966946
Revenue growth (YoY)+21.2%+14.9%+2.4%+8.1%-2.6%-0.8%--
Other income72.7761.6335.7131.8233.9143.7639.4635.06
Total expenses780631642655639554635656
EBITDA400293347368335251331290
EBITDA margin+33.9%+31.7%+35.1%+35.9%+34.4%+31.2%+34.2%+30.7%
Depreciation15.0215.8413.1720.3217.4315.5214.7218.80
Interest0.490.970.611.190.510.420.580.09
Profit before tax458338369378351279355306
Tax12384.6594.1810195.6573.8794.7677.77

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,1849389951,041980805974949
Revenue growth (YoY)+20.8%+16.6%+2.2%+9.7%-3.1%-1.2%--
Other income72.7843.7635.9550.1036.2143.7240.6835.07
EBITDA402296351371336251333292
EBITDA margin+34.0%+31.5%+35.3%+35.7%+34.3%+31.2%+34.2%+30.7%
Depreciation15.0215.8413.1720.3217.4315.5214.7218.80
Interest0.490.970.611.190.510.420.580.09
Profit before tax459322373400354279359308
Tax12385.2795.2410496.5173.9795.7078.22
Net profit336237278296257205263230
EPS (β‚Ή)19.8314.0016.4017.4515.0212.1015.5213.57
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,8223,7493,4543,2523,2782,9263,224
Revenue growth+1.9%+8.6%+6.2%-0.8%+12.1%-9.3%-
Other income1661511421141,423218626
Total expenses2,5122,5722,7082,4592,5382,5373,455
Employee cost607580624595610616629
EBITDA1,3091,177745793740389(231)
EBITDA margin+34.3%+31.4%+21.6%+24.4%+22.6%+13.3%-7.2%
Depreciation66.4466.7969.6865.7768.1978.6082.68
Interest2.731.311.801.812.003.536.34
Profit before tax1,4061,2608168392,093525306
Tax370332226229398167213
Net profit9628746575901,684476144
Net profit margin+25.2%+23.3%+19.0%+18.1%+51.4%+16.3%+4.5%
EPS (β‚Ή)61.1554.7634.8336.05100.0421.145.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital169169169169169169169
Reserves & surplus2,0981,7821,6081,5722,4941,3091,651
Shareholders' funds (net worth)2,2671,9511,7781,7412,6631,4781,821
Minority interest0.000.000.000.000.000.000.00
Secured loans0.000.000.000.000.000.000.00
Unsecured loans33.279.9518.6715.5420.0834.630.18
Total debt33.279.9518.6715.5420.0834.630.18
Total liabilities2,5612,2102,0442,0122,9471,7742,111
Assets
Gross block7006696666365946031,472
Net block281284321330331387758
Capital work in progress32.9314.3213.9320.3130.5013.21120
Investments1,3921,1188135183660.000.00
Inventories458482525460535547483
Sundry debtors27329322219220521699.80
Cash & bank balances1,3911,4041,0631,1562,4851,1581,083
Loans & advances93.55114175168118282109
Total current assets2,2152,2921,9851,9763,3422,2031,775
Total current liabilities1,7631,8981,5131,3141,6861,3401,024
Net working capital4523944726621,656862751
Total assets2,5612,2102,0442,0122,9471,7742,111
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash53964.1734.9428640510598.78
Net cash from operating activities9031,290582484811578490
Net cash from investing activities397(45.80)8.71808(406)418(56.84)
Net cash from financing activities(737)(769)(562)(1,543)(524)(696)(428)
Net change in cash56347529.23(251)(119)3006.03
Closing cash1,3911,4041,0631,1562,4851,1581,083
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.9%+8.6%+6.2%-0.8%+12.1%-9.3%-
EBITDA growth+11.2%+58.0%-6.0%+7.1%+90.4%+268.3%-
PBT growth+11.6%+54.4%-2.8%-59.9%+298.8%+71.7%-55.2%
Net income growth+10.1%+33.1%+11.4%-65.0%+253.7%+231.1%-
Revenue CAGR (3Y)+5.5%+4.6%+5.7%+0.3%+1.6%+0.6%+3.5%
EBITDA CAGR (3Y)+18.2%+16.7%+24.2%-+8.4%-8.4%-
Profitability & leverage
Net income margin+27.1%+24.7%+17.1%+18.8%+51.7%+12.2%+2.9%
Return on capital employed+59.1%+59.3%+45.0%+33.9%+32.6%+32.4%+28.5%
Return on net worth+49.1%+49.8%+37.3%+27.7%+81.3%+28.9%+7.3%
Debt / equity0.010.010.010.010.010.010.00
Long-term debt / equity0.000.000.000.000.010.010.00
Interest cover0.220.120.270.250.301.14-2.02
Efficiency & per share
Fixed asset turnover5.585.625.315.295.482.823.17
Inventory turnover8.147.457.016.546.065.686.65
Debtors turnover13.5114.5716.6716.3615.5818.5529.27
EPS (β‚Ή)61.1554.7634.8336.05100.0421.145.50
Dividend per share (β‚Ή)57.0054.0032.0032.0090.0030.0040.00
Book value per share (β‚Ή)133.85115.19104.93102.79157.1987.26107.47
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue1,1809249891,023974805966946
Revenue growth (YoY)+21.2%+14.9%+2.4%+8.1%-2.6%-0.8%--
Other income72.7761.6335.7131.8233.9143.7639.4635.06
Total expenses780631642655639554635656
EBITDA400293347368335251331290
EBITDA margin+33.9%+31.7%+35.1%+35.9%+34.4%+31.2%+34.2%+30.7%
Depreciation15.0215.8413.1720.3217.4315.5214.7218.80
Interest0.490.970.611.190.510.420.580.09
Profit before tax458338369378351279355306
Tax12384.6594.1810195.6573.8794.7677.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,7903,7233,4073,2163,2182,9203,225
Revenue growth+1.8%+9.3%+5.9%-0.0%+10.2%-9.4%-
Other income1451471431151,423218624
Total expenses2,4902,5542,6702,4282,4832,5323,438
Employee cost607580624595610616629
EBITDA1,3001,169737788734389(213)
EBITDA margin+34.3%+31.4%+21.6%+24.5%+22.8%+13.3%-6.6%
Depreciation66.4466.7969.6865.7768.1978.6082.68
Interest2.731.311.801.811.993.536.34
Profit before tax1,3761,2488098352,087524322
Tax364329224228397167212
Net profit9088276515871,679475197
Net profit margin+24.0%+22.2%+19.1%+18.2%+52.2%+16.3%+6.1%
EPS (β‚Ή)59.7354.2534.5135.8899.7921.116.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital169169169169169169169
Reserves & surplus2,0721,7801,6151,5842,5081,3281,671
Shareholders' funds (net worth)2,2411,9491,7841,7532,6781,4971,840
Secured loans0.000.000.000.000.000.000.00
Unsecured loans33.279.9518.6715.5420.0834.630.18
Total debt33.279.9518.6715.5420.0834.630.18
Total liabilities2,5342,2082,0492,0232,9611,7922,130
Assets
Gross block7006696836365946031,455
Net block281284321330331387758
Capital work in progress32.9314.3213.9320.3130.5013.21120
Investments1,4161,14383854339024.4924.49
Inventories430463514438513523483
Sundry debtors27329322219220521699.80
Cash & bank balances1,3551,4011,0611,1512,4791,1581,066
Loans & advances93.90109155168108275108
Total current assets2,1522,2651,9531,9483,3052,1711,757
Total current liabilities1,7411,8931,4991,3051,6621,3051,002
Net working capital4113724546441,643866755
Total assets2,5342,2082,0492,0232,9611,7922,130
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash53662.1529.7428140598.0397.78
Net cash from operating activities8811,280579488820595491
Net cash from investing activities385(36.53)14.97805(420)408(63.10)
Net cash from financing activities(737)(769)(562)(1,544)(524)(696)(428)
Net change in cash53047432.41(251)(124)3070.25
Closing cash1,3551,4011,0611,1512,4791,1581,066
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+1.8%+9.3%+5.9%-0.0%+10.2%-9.4%-
EBITDA growth+11.2%+58.6%-6.4%+7.3%+89.0%+282.5%-
PBT growth+10.2%+54.3%-3.2%-60.0%+298.3%+62.5%-51.4%
Net income growth+9.8%+27.0%+11.0%-65.1%+253.3%+141.1%-
Revenue CAGR (3Y)+5.6%+5.0%+5.3%-0.1%+0.9%+0.6%+3.6%
EBITDA CAGR (3Y)+18.2%+16.8%+23.8%-+9.2%-8.6%-
Profitability & leverage
Net income margin+26.7%+24.7%+17.2%+18.9%+52.5%+12.2%+3.4%
Return on capital employed+58.2%+58.7%+44.4%+33.6%+32.1%+32.1%+28.4%
Return on net worth+48.3%+49.2%+36.8%+27.4%+80.5%+28.5%+9.9%
Debt / equity0.010.010.010.010.010.010.00
Long-term debt / equity0.000.000.000.000.010.010.00
Interest cover0.220.120.270.250.301.14-2.15
Efficiency & per share
Fixed asset turnover5.545.515.175.235.382.843.20
Inventory turnover8.487.627.166.776.215.806.65
Debtors turnover13.4014.4716.4416.1815.2918.5229.28
EPS (β‚Ή)59.7354.2534.5135.8899.7921.116.50
Dividend per share (β‚Ή)57.0054.0032.0032.0090.0030.0040.00
Book value per share (β‚Ή)132.30115.06105.31103.48158.0688.37108.62

Investments & Acquisitions by GSK

GSK has strategically engaged in corporate development activities, having acquired 23 companies. Notable acquisitions include 35Pharma, Affinivax and Aiolos Bio.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
nuvalent.comCambridge, United States2017Jun 2026$10.6B
Designs and develops innovative biologics for unmet medical needs in healthcare.
35pharma.comMontreal, Canada2021Feb 2026$950M
Developer of RNA therapeutics to treat undruggable diseases
elsiebio.comSan Diego, United States2021Jun 2024$50M
Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions
aiolosbio.comBoston, United States2023Jan 2024β€’β€’β€’β€’
GSK is engaged in developing biopharmaceutical solutions globally.
bellushealth.comLaval, Canada1993Apr 2023$2B
Aircraft engines and traditional propulsion systems are manufactured.
solutionf.comVenelles, France1985Jul 2022β€’β€’β€’β€’
Technology-based conjugate vaccines against infectious diseases are developed.
affinivax.comCambridge, United States2013May 2022$2.1B
Oncology therapeutics for cancer treatment and nausea prevention are developed.
tesarobio.comWaltham, United States2010Dec 2018$5.1B
Developer of vaccines against a range of infectious diseases
okairos.comBasel, Switzerland2007β€’β€’β€’β€’
Bioconjugate vaccines for bacterial infections are developed using proprietary technology.
glycovaxyn.comSchlieren, Switzerland2004β€’β€’β€’β€’
Premium access

Complete acquisition details for GSK

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of GSK

14 dated milestones of GSK across 23 years, from founding to its latest funding, stage changes and deals.

  1. IPO Lists on the stock exchange (IPO).
  2. Funding First funding round of $394K.
  3. Acquisition Acquires TESARO.
  4. Exit Acquired by Unilever.
  5. Acquisition Acquires GSK.
  6. Acquisition Acquires Affinivax.
  7. Acquisition Acquires Solution F.
  8. Acquisition Acquires GSK.
  9. Funding Latest funding round, Grant, of $415K.
  10. Acquisition Acquires Aiolos Bio.
  11. Acquisition Acquires Elsie Biotechnologies.
  12. Acquisition Acquires GSK.
  13. Acquisition Acquires 35Pharma.
  14. Acquisition Acquires Nuvalent.

Web traffic of GSK

The website of GSK (gsk.com) receives about 1.3M visits a month and ranks #56,834 among all websites worldwide, #1,503 in Health.

  • Monthly visits
    1.3M

    ▲ 54.6% vs previous month

  • Unique visitors
    374.3K

    per month

  • Global rank
    #56,834

    among all websites

  • Category rank
    #1,503

    Health · Health

Similar websites

Websites whose visitors overlap most with GSK. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
abbott.com
100%
917.2K#65,577View details
bms.com
98%
809.8K#67,210View details
lilly.com
98%
4.9M#13,252View details
novartis.com
94%
948.8K#58,822View details
boehringer-ingelheim.com
93%
1.6M#39,825View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 40 similar websites and full traffic analytics for GSK

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Gsk

GLAXO: Q2 REVENUE 11.84B RUPEES VS 9.8B (YOY)
Exchange Update β€’ 16 days ago
GLAXO: Q2 CONS NET PROFIT 3.36B RUPEES VS 2.57B (YOY)
Exchange Update β€’ 16 days ago
GLAXO: Q2 EBITDA 4B RUPEES VS 3.36B (YOY); Q2 EBITDA MARGIN 33.97% VS 34.26% (YOY)
Exchange Update β€’ 16 days ago
Premium access

Complete news archive for GSK

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about GSK

GSK was founded in 1715 and raised its 1st funding round 293 years after it was founded.

GSK is headquartered in Brentford, United Kingdom. It is registered at Brentford, England, United Kingdom.

Dame Emma Walmsley is the CEO of GSK, as recorded in our data.

GSK has 91,864 employees.

The primary company behind GSK, Glaxosmithkline Pharmaceuticals Limited, reported revenue of β‚Ή3,988 Cr for FY 2026, up 2% year on year.

Founded in 1715, GSK operates in the pharmaceutical sector, with a focus on research, development, clinical trials, and commercialization of medicines and vaccines. Treatments are provided for respiratory, immunology, inflammatory, oncology, HIV, and infectious diseases. Global access to products is emphasized, alongside sustainable practices, from its base in Brentford, United Kingdom.

Yes, GSK is publicly traded on LSE under the ticker symbol GSK.

GSK has made 23 acquisitions, including 35Pharma, Affinivax, and Aiolos Bio.

GSK has 10 investors. Key investors include Unilever, Elliott Management, Scottish Enterprise, CARB-X, and European Union.

GSK operates through Glaxosmithkline Pharmaceuticals Limited.

Yes. GSK was acquired by Unilever in December 2018.

The legal entities of GSK currently have 9 directors, including Subesh Ronald Williams, Renu Sud Karnad, Sunita Maheshwari and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available